Skip to main content
SpringerLink
Log in

TNF-α inhibitors

  • Chapter
Antirheumatic Therapy: Actions and Outcomes

Part of the book series: Progress in Inflammation Research ((PIR))

  • 680 Accesses

Abstract

The development of anti-TNF-α therapy has resulted in the potential to radically alter the course of inflammatory diseasessuch as rheumatoid arthritis (RA). Currently there arethree anti-TNF-α agents available for clinical use: infliximab, a chimeric anti-TNF-α mAb; etanercept, a soluble TNF-receptor construct; and adalimumab (formerly knowas D2E7), a humananti-TNF-α mAb. All three agents block the ability of TNF to bind to the cell and prevent TNF from stimulating the cell to produce the biochemical agents that are ultimately responsible for the clinical markers of RA: inflammation, tissue damage, pain, stiffness, swelling, tenderness, and eventual deformation of the joint and patient disability.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Möhler KM, Torrance DS, Smith CA, Goodwin RG, Stremler KE, Fung VP, Madani H, Widmer MB (1993) Soluble tumor necrosis factor (TNF) receptors are effective theraupetic agents in lethal endothexemia and function simultaneously as both TNF carriers and TNF antagonists. J. Immunol 51: 1548–1561

    Google Scholar 

  2. den Broeder AA, Joosten LAB, Saxne T, Heinegard D, Heinegard D, Fenner H, Miltenburg AM, Frasa WL, van Tits LJ, Buurman WA et al (2002) Long term anti-tumour necrosis factor a monotherapy in rheumatoid arthritis: Effect on radiological course and prognosticvalue of markersof cartilage turnover andendothelial activation. Ann Rheum Dis 61: 311–318

    Article  Google Scholar 

  3. Paleolog EM, Hunt M, Elliot MJ, Feldmann M, Maini R, Woody J (1996) Deactivation of vascularendothelium bymonoclonalanti-tumor necrosis factor-α antibody in rheumatoid arthritis. Arthritis Rheum 39: 1082–1091

    Article  CAS  PubMed  Google Scholar 

  4. Tak PP, Taylor PC, Breedveld FC, Smeets TJM, Daha MR, Smeets TJ, Daha MR, Kluin PM, Meinders AE, Maini RN (1996) Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor a monoclonal antibody treatmentin patients with rheumatoid arthritis. Arthritis Rheum 39: 1077–1081

    Article  CAS  PubMed  Google Scholar 

  5. Paleolog E, Young S, McClosekey RV et al (1998) Angiogenesis as a therapeutic target in rheumatoid arthritis: serum vascular endothelial growth factor is decreased by anti-TNF a therapy. Clin Exp Rheumatol 16: 232

    Google Scholar 

  6. van Vollenhoven R, Harju A, Brannemark S, Klareskog L (2003) Treatment with infliximab (remicade) when etanercept (enbrel) has failed or vice versa: Data from STURE registry showing that switching tumour necrosis factor a blockers can make sense. Ann Rheum Dis 62: 1195–1198

    Article  PubMed  Google Scholar 

  7. Maini RN, Breedveld FC, Kalden JR et al (1998) Therapeutic efficacy of multiple intraveneous infusions of anti-tumour necrosis factor-alpha monoclonal antibody combined withlow-dose weekly methotrexatein rheumatoid arthritis. Arthritis Rheum 41: 1552–1563

    Article  CAS  PubMed  Google Scholar 

  8. Maini R, St Clair EW, Breedweld F, Furst D, Kalden J, Weisman M, Smolen J, Emery P, Harriman G, Feldmann M et al (1999) Infliximab (chimeric anti-tumour necrosis factor a monoclonalantibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomized phase III trial. Lancet 354: 1932–1939

    Article  CAS  PubMed  Google Scholar 

  9. Kavanaugh A, St Clair EW, McCune WJ et al (2000) Chimeric anti-tumour necrosis factor a monoclonal antibody treatment of patients with rheumatoidarthritisreceiving methotrexate therapy. J. Rheumatol 27: 841–850

    CAS  PubMed  Google Scholar 

  10. St Clair E, Wagner C, Fasanmade A, Wang B, Schaible T, Kavanaugh A, Keystone E (2002) Relationship of serum infliximab concentrations to clinical improvementin rheumatoid arthritis. Arthritis Rheum 46: 1451–1459

    Article  Google Scholar 

  11. Korth-Bradley, Abbe SR, Roberta KH, Simcoe DK, Lebsack ME (2000) The pharmacokinetics of Etanercept in healthy volunteers. Ann Pharmacothar 34: 161–164

    Article  CAS  Google Scholar 

  12. Jobanputra P, Barton P, Bryan S, Burls A (2002) The effectiveness of infliximab and etanercept for the treatment of rheumatoid arthritis: A systemicreview and economic evaluation. Health Technol Assess 6(21): 1–110

    CAS  PubMed  Google Scholar 

  13. Brennan A, Browne KA, Green PA, Jaspar JM, Maini RN, Feldman M (1997) Reduction of serum matrix metalloproteinase 1 and matrix metalloproteinase 3 in rheumatoid arthritis patients following anti-tumour factor-alpha (cA2) therapy. Br J Rheumatol 36: 643–650

    Article  CAS  PubMed  Google Scholar 

  14. Elliott MJ, Maini RN, Feldman M (1994) Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factoralpha(cA2) versus placeboin rheumatoid arthritis. Lancet 344:1105–1110

    Article  CAS  PubMed  Google Scholar 

  15. Moreland LW, Margolies G, Heck LW, Saway A, Blosch C, Hanna R, Koopman WJ (1996) Recombinant soluble tumor necrosis factor receptor(p80) fusion protein: toxicity and dose finding trial in refractory rheumatoid arthritis. J. Rheumatol 23: 1849–1855

    CAS  PubMed  Google Scholar 

  16. Moreland LW, Baumgartner SW, Schiff MH et al(1997) Treatment of rheumatoid arthritis with a recombinant human tumour necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 337: 141–147

    Article  CAS  PubMed  Google Scholar 

  17. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, Smolen JS, Weisman M, Emery P, Feldmann M et al (2000) Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 343: 1594–1602

    Article  CAS  PubMed  Google Scholar 

  18. Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleischmann RM, Bulpitt KJ, Weaver AL, Keystone EC, Furst DE, Mease PJ et al(1999) Etanercepttherapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 130: 478–486

    CAS  PubMed  Google Scholar 

  19. Weinblatt ME, Kremer KM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, Jackson CG, Lange M, Bürge DJ (1999) A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 340: 253–259

    Article  CAS  PubMed  Google Scholar 

  20. Genovese MC, Bathon JM, Martin R, Fleischmann R, Tesser JR, Schiff MH, Keystone EC, Wasko MC, Moreland L W, Weaver AL et al (2002) Etanercept versus methotrexate in patients with early rheumatoid arthritis: Two year radiographic and clinical outcomes Arthritis Rheum 46: 1443–1450

    Article  CAS  PubMed  Google Scholar 

  21. Van de Putte LBA, Rau R, Breedveld FC, Kalden JR et al (2003) Efficacy and safety of the fully human anti-TNF-alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: A 12 week, phase II study. Ann Rheum Dis 62: 1168–1177

    Article  PubMed  Google Scholar 

  22. Weinblatt M, Keystone E, Furst D, Moreland L W, Weisman MH, Birbara CA, Teoh LA, Fischkoff SA, Chartash EK (2003) Adalimumab, a fully human anti-tumor necrosis factor a monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate. Arthritis Rheum 48: 35–45

    Article  CAS  PubMed  Google Scholar 

  23. Keystone E, Kavanaugh A, Sharp J, Tannenbaum H et al (2002) Adalimumab (D2E7), a fully human anti-TNFα monoclonal antibody, inhibits the progression of structural damage in patients with active rheumatoid arthritis despite concomitant methotrexate therapy. Arthritis Rheum 46 (suppl 9): S205 Abstract 468

    Google Scholar 

  24. Callahan LF (1998) The burden of rheumatoid arthritis: facts and figures. J. Rheumatol (Suppl) 53: 8–12

    CAS  Google Scholar 

  25. Blair J, Faulds D (1999) Etanercept. A review of its use in rheumatoid arthritis. Drugs 57: 945–966

    Article  Google Scholar 

  26. Nuijten MJ, Engelgriet P, Dujin K, Bruijn G, Wierz D, Koopmanschap M (2001) A costcost study comparing etanercept with infliximab in rheumatoid arthritis. Pharmacoeconomics 19: 1051–1064

    Article  CAS  PubMed  Google Scholar 

  27. Choi HK, Seeger JD, Kuntz KM (2002) A cost effectivenessanalysis of treatment options for methotrexate-naive rheumatoid arthritis. J. Rheumatol 29: 1156–1165

    PubMed  Google Scholar 

  28. Wong JB, Singh G, Kavanaugh A (2002) Estimating the cost-effectiveness of 54 weeks of infliximab for rheumatoid arthritis. Am J Med 113: 400–408

    Article  PubMed  Google Scholar 

  29. Kobelt G, Jönsson, Young A, Eberhardt K (2003) The cost-effectiveness of infliximab (remicade) in the treatment of rheumatoid arthritis in Sweden and United Kingdom based on the ATTRACT study. Rheumatol 42: 326–335

    Article  CAS  Google Scholar 

  30. Brennan A, Bansback N, Reynolds A, Conway P (2003) MO’Delling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK. Rheumatol 42:1–13

    Article  Google Scholar 

  31. Kremer JM (2001) Rational use of new and existing disease-modifying agentsin rheumatoid arthritis. Ann Intern Med 134: 695–706

    CAS  PubMed  Google Scholar 

  32. Bean AG, Roach DR, Briscoe H, France MP, Korner H, Sedgwick JD, Britton WJ (1999) Structural deficiencies in granuloma formationin TNF gene-targeted mice underlie the heightened susceptibility to aerosol Mycobacterium tuberculosis infection. J Immunol 162: 3504–3511

    CAS  PubMed  Google Scholar 

  33. Ehlers S, Benini J, Kutsch S, Endres R, Rietschel ET, Pfeffer K (1999) Fatal granuloma necrosis despite intact antibacterial functions in TNFR p55-deficient mice chronically infected with M. Avium. Infect Immun 67: 3571–3579

    CAS  PubMed  Google Scholar 

  34. Chen W, Havell EA, Harmsen AG (1992) Importance of endogeneous tumor necrosis factor and gamma interferon in host resistance against Pneumocystis Carinii infection. Infect Immun 60: 1279–1284

    CAS  PubMed  Google Scholar 

  35. Allendoerfer R, Deepe GS (1998) Blockade of endogeneous TNF-α exacerbates primary and secondary pulmonary histoplasmosis by differential mechanisms. J. Immunol 160: 6072–6082

    CAS  PubMed  Google Scholar 

  36. Rothe J, Lesslauer W, Lotscher H, Lang Y, Koebel P, Kontgen F, Althage A, Zinkernagel R, Steinmetz M, Bluethmann H (1993) Mice lacking the tumour necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes. Nature 364: 798–802

    Article  CAS  PubMed  Google Scholar 

  37. Skerret SJ, Bagby GJ, Schmidt RA, Nelson S (1997) Antibody-mediated depletion of tumour necrosis factor impairs pulmonary host defenses to Legionella pneumophila. J Infect Dis 176: 1019–1028

    Article  Google Scholar 

  38. Wolfe F, Mitchell D, Sibley J (1994) The mortality of rheumatoid arthritis. Arthritis Rheum 37: 481–494

    Article  CAS  PubMed  Google Scholar 

  39. Doran MF, Crowson CS, Pond GR et al (2002) Frequency of infection in patients with rheumatoid arthritis compared with controls. Arthritis Rheum 46: 2287–2293

    Article  PubMed  Google Scholar 

  40. Kavanaugh A, Keystone E (2003) The safety of biologic agents in early rheumatoid arthritis. Clin Exp Rheumatol 21: s203–s208

    CAS  PubMed  Google Scholar 

  41. Keane J, Gerbson S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, Siegel JN, Braun MM (2001) Tuberculosis associated with infliximab, a tumor necrosis factor neutralizing agent. N Engl J Med 345: 1098–1104

    Article  CAS  PubMed  Google Scholar 

  42. Charles PJ, Smeenk RJT, De Jong J, Feldmann M, Maini RN (2000) Assessment of antibodies to DsDNA induced in rheumatoid arthritis (RA) patients following treatment with infliximab, a monoclonal antibody to TNF alpha. Arthritis Rheum 43: 2383–2390

    Article  CAS  PubMed  Google Scholar 

  43. Mohan N, Edwards ET, Cupps TR, Oliverio PJ, Sandberg G, Crayton H, Richert JR, Siegel JN (2001) Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum 44: 2862–2869

    Article  CAS  PubMed  Google Scholar 

  44. van Oosten BW, Barkhof F, Truyen L, Boringa JB, Bertelsmann FW, von Blomberg BM, Woody JN, Hartung HP, Polman CH (1996) Increased MRI activity and immune activation in two multiple sclerosis patients treated withmonoclonal anti-tumor necrosis factor antibody cA2. Neurology 47: 1531–1534

    PubMed  Google Scholar 

  45. The Lenercept Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group (1999)TNF neutralization in MS: Results of a randomized, placebo-controlled multicenter trial. Neurology 53:457–465

    Google Scholar 

  46. Moreland LM, Cohen SB, Baumgartner SW, Tindall EA, Bulpitt K, Martin R, Weinblatt M, Taborn J, Weaver A, Burge DJ et al (2001) Long-term safety and efficacy of etanercept in patients with rheumatoid arthritis. J. Rheumatol 28: 1238–1244

    CAS  PubMed  Google Scholar 

  47. Lovell DJ, Giannini EH, Reiff A, Cawkwell GD, Silverman ED, Nocton JJ, Stein LD, Gedalia A, Ilowite NT, Wallace CA et al (2000) Etanercept in children with polyarticular juvenile rheumatoid arthritis. N Engl J Med 342: 763–769

    Article  CAS  PubMed  Google Scholar 

  48. Kietz DA, Pepmueller PH, Moore TL (2002) Therapeutic use of etanercept in polyarticular course juvenile idiopathic arthritis over a two year period. Ann Rheum Dis 61: 171–173

    Article  CAS  PubMed  Google Scholar 

  49. Brandt J, Haibel H, Reddig J, Sieper J, Braun J (2002) Successful short term treatment of severe undifferentiated spondyloarthropathy with theanti-tumour necrosis factoralpha monoclonal antibody infliximab. J. Rheumatol 29: 118–122

    CAS  PubMed  Google Scholar 

  50. Mease PJ, Goffe B S, Metz J, VanderStoep A, Finck B, Buge DJ (2000) Etanercept in the treatment of psoriatic arthritis and psoriasis: Randomizedtrial. Lancet 356: 385–390

    Article  CAS  PubMed  Google Scholar 

  51. Van den Bosch F, Kruithof E, Baeten D, Herssens A, de Keyser F, Mielants H, Veys EM (2002) Randomized double-blind comparisonof chimeric monoclonal antibody to tumor necrosis factor (infliximab) versus placebo in active spondyloarthropathy. Arthritis Rheum 46: 755–765

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Rheumatology, Allergy and Immunology, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA, 92093-0943, USA

    Zuhre Tutuncu & Arthur Kavanaugh

Authors
  1. Zuhre Tutuncu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Arthur Kavanaugh
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Clinical Pharmacology and Toxicology, St. Vincent’s Hospital Sydney, Victoria Street Darlinghurst, Sydney, NSW, 2010, Australia

    Richard O. Day

  2. 546 Dept. of Rheumatology, University Hospital Nijmegen, P.O. Box 9101, 6500 HB, Nijmegen, The Netherlands

    Piet L. C. M. van Riel

  3. Carl M.Pearson Professor of Rheumatology, 1000 Veteran Ave Rm 32-59, Los Angeles, CA, 90025-1670, USA

    Daniel E. Fürst

  4. Department of Rheumatology, St Vicent’s University Hospital, Elm Park, Dublin 4, Ireland

    Barry Bresnihan

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Birkhäuser Verlag Basel/Switzerland

About this chapter

Cite this chapter

Tutuncu, Z., Kavanaugh, A. (2005). TNF-α inhibitors. In: Day, R.O., Fürst, D.E., van Riel, P.L.C.M., Bresnihan, B. (eds) Antirheumatic Therapy: Actions and Outcomes. Progress in Inflammation Research. Birkhäuser Basel. https://doi.org/10.1007/978-3-7643-7726-7_14

Download citation

  • DOI: https://doi.org/10.1007/978-3-7643-7726-7_14

  • Publisher Name: Birkhäuser Basel

  • Print ISBN: 978-3-7643-6595-0

  • Online ISBN: 978-3-7643-7726-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation